| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:46 | Novartis CEO leans on surge of pipeline readouts to quell growth fears | ||
| 12:46 | Sanofi rumoured to be eyeing high-profile Insmed takeover | ||
| Do | Recursion CEO details novel Phase III endpoint for rare disease drug | ||
| Do | Geopolitical pressures and greater buyer selectivity hamper M&A deal closure rates | ||
| Do | Ellipses Pharma plots London listing that could end British biotech IPO drought | ||
| Do | AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics | ||
| Do | Pfizer inks $2.6bn autoimmune deal with China's Starna for CAR-T therapies | ||
| Do | Bridging gaps in rare disease drug access requires strategic rethink | ||
| Do | Genomics, Vertex extend drug discovery alliance in $220m deal | ||
| Do | FDA approves Regeneron's Livsayis for generalised myasthenia gravis | ||
| Mi | European capital markets require efforts to attract biotech listings | ||
| Mi | GSK's $10.6bn Nuvalent bet pays off with second lung cancer drug approval | ||
| Mi | Isomorphic Labs raises $5bn to advance drug pipeline | ||
| Mi | Revolution Medicines' Rasonque gains EC authorisation for pancreatic cancer | ||
| Di | Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio | ||
| Di | Pfizer CEO: 'China will be my major competition by 2030' | ||
| Di | Seawolf Therapeutics and Sanofi agree $1.2bn drug deal | ||
| Di | UK biotech sector calls on government to support sector's growth on home soil | ||
| Di | Lilly agrees to acquire Calytrix Bio for $1.5bn | ||
| Mo | J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences | ||
| Mo | RevMed CEO on tackling "complex" launch for wonder pancreatic drug | ||
| Mo | Flagship Pioneering expands to UK with £100m AI-native lab | ||
| Mo | Sofinnova Partners backs European life sciences sector with €725M raise | ||
| Mo | AstraZeneca secures FDA approval for Imfinzi combo in MIBC | ||
| Mo | FDA rejects Summit's ivonescimab application for lung cancer |